Chronic Idiopathic Constipation Therapeutic Market to Grow with a CAGR of 7.80% through 2028
Regulatory support, global reach, and a
patient-centric approach are expected to drive the Global Chronic Idiopathic
Constipation Therapeutic Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Chronic
Idiopathic Constipation Therapeutic Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Chronic
Idiopathic Constipation Therapeutic Market stood at USD 545.23 million in 2022
and is anticipated to grow with a CAGR of 7.80% in the forecast period,
2024-2028. This can be attributed to personalized medicine. The shift towards
personalized medicine is another driving force in the CIC therapeutic market.
Healthcare providers are increasingly tailoring treatment plans to individual
patient needs and preferences. This approach ensures that patients receive the
most effective and suitable therapies, enhancing treatment outcomes and patient
satisfaction.
Furthermore, combination therapies, involving the use
of multiple treatment modalities, may become more prevalent. These approaches
can provide synergistic benefits, addressing different aspects of CIC and
potentially leading to better outcomes for patients.
The growth of the market is being driven by an
increase in clinical trials and the approval of drug candidates by
pharmaceutical companies to address the unmet medical needs in the treatment of
chronic idiopathic constipation. For instance, in March 2018, Shire plc
received approval from the U.S. FDA for its drug candidate, SHP555
(prucalopride), aimed at treating chronic idiopathic constipation in adults.
Additionally, in 2015, SHP555 (prucalopride) received the green light from the
European Commission for its use in treating chronic constipation in adults who
have not responded well to laxative treatment.
Furthermore, Renexxion is currently conducting a phase
2 clinical trial for Naronapride (ATI-7505) to address multiple
gastrointestinal disorders, including chronic idiopathic constipation. In 2017,
the FDA also approved Linzess (linaclotide), a joint effort between Ironwood
and Allergan, for the treatment of chronic idiopathic constipation. Despite
these advancements, it is noteworthy that 50% of chronic constipation patients
express dissatisfaction with their current treatments, primarily due to their
perceived lack of effectiveness, highlighting the ongoing need for more
efficient and safer therapeutic options. Nevertheless, the utilization of
alternative therapies such as home-based remedies and herbal medications like
herbal laxatives and probiotic foods is anticipated to be a significant factor
impeding market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Chronic Idiopathic Constipation Therapeutic Market.”
Based on its drug class, Bulk-forming agents are
poised to secure a substantial market share in the Global Chronic Idiopathic
Constipation Therapeutic Market during the forecast period for several
compelling reasons. Firstly, the increasing prevalence of chronic idiopathic
constipation across the globe has driven the demand for effective and safe
therapeutic solutions. Bulk-forming agents, with their ability to promote
regular bowel movements by adding bulk to stool and enhancing overall
gastrointestinal function, are increasingly preferred by both healthcare
professionals and patients. Furthermore, these agents are well-tolerated, with
minimal side effects, making them a preferred choice for long-term management.
Additionally, the growing awareness of the importance of preventive healthcare
and the trend towards natural and non-pharmacological remedies have further
bolstered the adoption of bulk-forming agents. As a result, their significant
market presence is expected to persist and even expand during the forecast
period, solidifying their position as a vital component of the chronic
idiopathic constipation therapeutic market.
Based on distribution channel, Hospital pharmacies are
poised to capture a substantial market share in the Global Chronic Idiopathic
Constipation Therapeutic Market during the forecast period for several
compelling reasons. Firstly, hospitals serve as critical hubs for the diagnosis
and treatment of chronic idiopathic constipation, providing a centralized point
for patient care. The convenience and accessibility of hospital pharmacies make
them a preferred choice for healthcare professionals to procure and dispense
therapeutic solutions promptly. Moreover, hospitals often stock a wide range of
pharmaceutical products, including specialized medications for chronic
constipation, thereby meeting the diverse needs of patients. Additionally, the
increasing burden of chronic idiopathic constipation worldwide is leading to a
higher number of patients seeking care in hospitals, further boosting the
demand for therapeutic options available through hospital pharmacies. Overall,
the strategic position of hospital pharmacies as integral components of the
healthcare system positions them to witness significant market share growth in
the chronic idiopathic constipation therapeutic market during the forecast
period.
Major companies operating in Global Chronic
Idiopathic Constipation Therapeutic Market are:
- GSK PLC
- Astellas Pharma Inc
- Synergy Pharmaceuticals Inc.
- Bayer AG
- Allergan PLC
- Sanofi SA
- Pfizer Inc
- Takeda Pharmaceutical Co Ltd
- Zydus Lifesciences Ltd
- Boehringer Ingelheim GmbH
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The future of the Global Chronic Idiopathic
Constipation Therapeutic Market is promising, with exciting trends on the
horizon. From the rise of biological therapies and personalized medicine to the
increasing focus on digital health solutions and regulatory support for
innovation, these trends are set to improve the lives of those living with CIC.
As research and development efforts continue to advance, a brighter future for
individuals seeking effective treatment for this common gastrointestinal disorder
can be anticipated,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Chronic Idiopathic Constipation Therapeutic Market
By Drug
Class (Bulk-Forming Agents, Emollients, Laxatives, Osmotic Agents), By Route of
Administration (Oral, Parenteral), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Chronic Idiopathic Constipation
Therapeutic Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Chronic Idiopathic
Constipation Therapeutic Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com